IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This study has been terminated.
(Replaced with another study)
Sponsor:
Masonic Cancer Center, University of Minnesota
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00290628
First received: February 9, 2006
Last updated: October 9, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This clinical trial is studying how well donor umbilical cord blood transplant works in treating patients with hematologic cancer.
| Condition | Intervention |
|---|---|
| Chronic Myeloproliferative Disorders Diamond-blackfan Anemia Fanconi Anemia Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases | Drug: anti-thymocyte globulin Drug: busulfan Drug: cyclophosphamide Drug: cyclosporine Drug: filgrastim Drug: melphalan Drug: methylprednisolone Drug: mycophenolate mofetil Procedure: radiation therapy Procedure: umbilical cord blood transplantation |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Transplantation of Umbilical Cord Blood From Related and Unrelated Donors |
Resource links provided by NLM:
Genetics Home Reference related topics:
Fanconi anemia
Genetic and Rare Diseases Information Center resources:
Myeloid Leukemia
Acute Myeloid Leukemia
Acute Non Lymphoblastic Leukemia
Myelofibrosis
Multiple Myeloma
Lymphosarcoma
Follicular Lymphoma
B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Marginal Zone Lymphoma
Chronic Lymphocytic Leukemia
Leukemia, B-cell, Chronic
Mantle Cell Lymphoma
Myelodysplastic Syndromes
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Homologous Wasting Disease
Hodgkin Lymphoma
Hodgkin Lymphoma, Childhood
Fanconi Anemia
Congenital Aplastic Anemia
Fanconi Syndrome
Lymphoma, Large-cell
Chronic Myeloproliferative Disorders
Childhood Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Cutaneous T-cell Lymphoma
Juvenile Myelomonocytic Leukemia
Lymphoblastic Lymphoma
Burkitt Lymphoma
Mycosis Fungoides
Sezary Syndrome
Diamond-Blackfan Anemia
Plasmablastic Lymphoma
Lymphoma, Large-cell, Immunoblastic
Hairy Cell Leukemia
Myelodysplastic/myeloproliferative Disease
Chronic Neutrophilic Leukemia
Anaplastic Plasmacytoma
Nephropathic Cystinosis
Primary Fanconi Syndrome
Pure Red Cell Aplasia
U.S. FDA Resources
Further study details as provided by Masonic Cancer Center, University of Minnesota:
| Enrollment: | 43 |
| Study Start Date: | October 1999 |
| Study Completion Date: | April 2007 |
| Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | up to 45 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
-
Diagnosis of 1 of the following:
-
Leukemia including, but not limited to, the following subtypes:
- Chronic myelogenous leukemia
- Acute myeloid leukemia (primary or secondary)
- Acute lymphoblastic leukemia
- Lymphoma
- Myelodysplastic syndrome
- Aplastic anemia
- Fanconi's anemia
- Diamond-Blackfan anemia
- Inborn errors of metabolism (e.g., Hurler syndrome, Maroteaux-Lamy syndrome, myelodysplastic syndrome VI, metachromatic leukodystrophy, adrenoleukodystrophy, and globoid cell leukodystrophy)
- Immune deficiency disorders
-
- Patients must meet the eligibility requirements outlined in currently active treatment protocols of the University of Minnesota Bone Marrow Transplant Program
-
HLA-identical or 1, 2, or 3 antigen mismatched umbilical cord blood (UCB) donor with at least one DRB1 match available
- Unrelated or related donor
- UCB specimen must contain ≥ 2.0 x 10^7 nucleated cells/kg patient body weight
PATIENT CHARACTERISTICS:
- See Disease Characteristics
- No active infection
- No history of HIV infection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00290628
Please refer to this study by its ClinicalTrials.gov identifier: NCT00290628
Locations
| United States, Minnesota | |
| University of Minnesota Cancer Center | |
| Minneapolis, Minnesota, United States, 55455 | |
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Investigators
| Study Chair: | John E. Wagner, MD | Masonic Cancer Center, University of Minnesota |
More Information
| Responsible Party: | Masonic Cancer Center, University of Minnesota |
| ClinicalTrials.gov Identifier: | NCT00290628 History of Changes |
| Other Study ID Numbers: |
2000LS017 UMN-MT1999-28 |
| Study First Received: | February 9, 2006 |
| Last Updated: | October 9, 2012 |
Keywords provided by Masonic Cancer Center, University of Minnesota:
|
graft versus host disease adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) accelerated phase chronic myelogenous leukemia adult acute lymphoblastic leukemia in remission adult acute myeloid leukemia in remission atypical chronic myeloid leukemia blastic phase chronic myelogenous leukemia childhood acute lymphoblastic leukemia in remission childhood acute myeloid leukemia in remission childhood chronic myelogenous leukemia chronic eosinophilic leukemia |
chronic idiopathic myelofibrosis chronic myelomonocytic leukemia chronic neutrophilic leukemia chronic phase chronic myelogenous leukemia de novo myelodysplastic syndromes extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue juvenile myelomonocytic leukemia myelodysplastic/myeloproliferative disease, unclassifiable nodal marginal zone B-cell lymphoma noncontiguous stage II adult Burkitt lymphoma noncontiguous stage II adult diffuse large cell lymphoma noncontiguous stage II adult diffuse mixed cell lymphoma noncontiguous stage II adult diffuse small cleaved cell lymphoma noncontiguous stage II adult immunoblastic large cell lymphoma noncontiguous stage II adult lymphoblastic lymphoma |
Additional relevant MeSH terms:
|
Lymphoma Syndrome Leukemia Multiple Myeloma Neoplasms, Plasma Cell Anemia Myelodysplastic Syndromes Preleukemia Graft vs Host Disease Plasmacytoma Myeloproliferative Disorders Fanconi Anemia Fanconi Syndrome Myelodysplastic-Myeloproliferative Diseases Anemia, Diamond-Blackfan |
Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Disease Pathologic Processes Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders |
ClinicalTrials.gov processed this record on July 19, 2017